Paul G. Allen Frontiers Group [to 8 Aug 2020]
Could treatments aimed at Alzheimer’s disease help combat COVID-19?
August 5, 2020
A team of cardiology researchers had a creative idea for a new way to treat dementia. Now they think it could help coronavirus patients too.


BARDA – U.S. Department of HHS [to 8 Aug 2020]
August 5, 2020: HHS, DOD Collaborate With Johnson & Johnson to Produce Millions of COVID-19 Investigational Vaccine Doses
[See Milestones above for detail]


BMGF – Gates Foundation [to 8 Aug 2020]
No new digest content identified.


Bill & Melinda Gates Medical Research Institute [to 8 Aug 2020]
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.


CARB-X [to 8 Aug 2020]
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
No new digest content identified.


CEPI – Coalition for Epidemic Preparedness Innovations [to 8 Aug 2020]
Latest News
CEPI survey assesses potential COVID-19 vaccine manufacturing capacity
05 Aug 2020
By The CEPI Sustainable Manufacturing Team
[See Milestones above for detail]


EDCTP [to 8 Aug 2020]
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
Latest news
No new digest content identified.


Emory Vaccine Center [to 8 Aug 2020]
Vaccine Center News
No new digest content identified.


European Medicines Agency [to 8 Aug 2020]
News & Press Releases
No new digest content identified.


European Vaccine Initiative [to 8 Aug 2020]
Latest News
No new digest content identified.


FDA [to 8 Aug 2020]
Press Announcements
August 7, 2020 – Coronavirus (COVID-19) Update: Daily Roundup August 7, 2020

August 6, 2020 – Coronavirus (COVID-19) Update: Daily Roundup August 6, 2020

August 5, 2020 – Coronavirus (COVID-19) Update: Daily Roundup August 5, 2020

August 4, 2020 – Coronavirus (COVID-19) Update: Daily Roundup August 4, 2020

August 3, 2020 – Coronavirus (COVID-19) Update: Daily Roundup August 3, 2020


Fondation Merieux [to 8 Aug 2020]
News, Events
No new digest content identified.


Gavi [to 8 Aug 2020]
News releases
6 August 2020
Up to 100 million COVID-19 vaccine doses to be made available for low- and middle-income countries as early as 2021
[See Milestones above for detail]


GHIT Fund [to 8 Aug 2020]
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that No new digest content identified.


Global Fund [to 8 Aug 2020]
The Global Fund Appoints Leading Global Health Experts to Head HIV, Tuberculosis and Malaria Teams
04 August 2020
The Global Fund has announced the appointment of three leading global health experts to head the organization’s HIV, Tuberculosis and Malaria teams to accelerate action to fight the three diseases.
Siobhan Crowley has been appointed Head of HIV, Eliud Wandwalo as Head of Tuberculosis and Scott Filler as Head of Malaria.
In their new roles, the appointees will develop and expand highly effective teams of senior disease advisors with the primary role of supporting Global Fund country teams, strengthening collaboration and alignment on key opportunities across the Global Fund Secretariat and deepening technical partner engagement to strengthen in-country results…


Hilleman Laboratories [to 8 Aug 2020]
No new digest content identified.


Human Vaccines Project [to 8 Aug 2020]
Press Release
2020 Michelson Prizes Support Groundbreaking Research by Young Scientists
August 3, 2020 – The Michelson Medical Research Foundation and the Human Vaccines Project are pleased to announce the 2020 Michelson Prizes for Human Immunology and Vaccine Research and support the outstanding research of two young scientists advancing human immunology, vaccine discovery and immunotherapy across major global diseases.
We live in historic times. 2020 will be remembered as the year the world endured an unprecedented pandemic with vast implications on the entire global community. The COVID pandemic has highlighted the critical need for groundbreaking research in immunology and vaccine discovery. Now, more than ever, it is crucial to support and cultivate young scientists advancing the fields of immunology, vaccinology, and immunotherapy. That is why the Michelson Medical Research Foundation and the Human Vaccines Project engage in an annual international search to identify and support the most promising projects from young investigators.
This year’s winners are Danika Hill, a research fellow at Monash University, and Michael Birnbaum, assistant professor at MIT. They will be awarded the 2020 Michelson Prize for Human Immunology and Vaccine Research, receiving $150,000 each…


IAVI [to 8 Aug 2020]
No new digest content identified.



International Coalition of Medicines Regulatory Authorities [ICMRA]
Selected Statements, Press Releases, Research
No new digest content identified.



International Generic and Biosimilar Medicines Association [IGBA]
No new digest content identified.



IFFIm issues NOK 2 billion in Vaccine Bonds for COVID-19 vaccine development
07 Jul 2020
IFFIm has issued NOK 2 billion in Vaccine Bonds to accelerate the availability of financing for urgent COVID-19 vaccine research and development by the Coalition for Epidemic Preparedness Innovations.


IFRC [to 8 Aug 2020]
Selected Press Releases, Announcements
Africa, South Africa
South Africa: Lessons of HIV/AIDS key to halting COVID-19 slide, says Red Cross
Johannesburg/Geneva, 7 August 2020 – A senior Red Cross official has warned that South Africa needed to learn lessons from the country’s fight against HIV/AIDS to help curb the rise in the number of people testing positive for COVID-19, as the number c …
7 August 2020

Asia Pacific, Bangladesh, India, Nepal
17.5 million affected by floods and threatened by disease in South Asia
Dhaka/Kuala Lumpur, 6 August 2020 – Monsoon floods are robbing millions of people of their homes and livelihoods, with mounting risk of more deadly disease outbreaks when health resources are stretched to breaking point by COVID-19. So far almost 17.5 …
6 August 2020


IRC International Rescue Committee [to 8 Aug 2020]
Media highlights
Press Release
As confirmed COVID cases more than double in July across African countries, a lack of testing in crisis-affected contexts keeps responders in the dark about the real spread of the disease, warns IRC
July 30, 2020
:: Each country in Africa where the IRC works has done less than 8,000 tests per million people, compared to the UK (205,782 per million), United Arab Emirates (472,590 per million), and Singapore (199,904 per million).
:: The countries in Africa where the IRC works which have done the least tests per million are Tanzania* (63 tests per million), Niger (373 tests per million), Chad (383 tests per million, DRC (467 tests per million), and Burundi (563 tests per million).
:: The UK has done up to 550 times more tests per million than the countries in Africa where the IRC works.
:: The WHO recommends at least 1 test per 1,000 people per week – while countries like Niger and South Sudan have done 1 test per every 2,680 and 930 people in total respectively.
:: The WHO recommends countries have a test positivity rate of 5% or under for at least 14 days; Most African countries where the IRC works are not meeting this target, such as Somalia (32%), DRC (21%), South Sudan (18%), Cote d’Ivoire (17%) and CAR (16%).
:: Despite efforts to expand testing capacities, hard-hit countries need additional resources and support from the international community to expand testing and mitigate the spread of COVID-19.


IVAC [to 8 Aug 2020]
DoVE Return on Investment (ROI) Publication Launch
August 2020
The Decade of Vaccine Economics (DoVE) Project, carried out by the Johns Hopkins Bloomberg School of Public Health’s International Vaccine Access Center (IVAC) for nearly ten years, has computed the return-on-investment for vaccines preventing 10 infectious diseases in 73 countries that have received support from Gavi, the Vaccine Alliance.


IVI [to 8 Aug 2020]
Selected IVI News & Announcements
No new digest content identified.


JEE Alliance [to 8 Aug 2020]
Selected News and Events
No new digest content identified.


MSF/Médecins Sans Frontières [to 8 Aug 2020]
Latest [Selected Announcements]
MSF supporting Beirut’s health services in wake of massive blast
Project Update 6 Aug 2020

Mediterranean migration
MSF and Sea-Watch announce collaboration to save lives at sea
Press Release 6 Aug 2020

South Africa
Western Cape begins to breathe after COVID-19 peak
Project Update 6 Aug 2020

Mosul: MSF works on dual front of COVID-19 and lifesaving medical care
Project Update 5 Aug 2020



Chasing COVID-19 in the Brazilian Amazon 4 Aug 2020


National Vaccine Program Office – U.S. HHS [to 8 Aug 2020]
NVAC Meetings
September 23-24, 2020 Meeting (Virtual)
February 4-5, 2021 NVAC Meeting
June 16-17, 2021 NVAC Meeting


NIH [to 8 Aug 2020]
Selected News Releases
Friday, August 7, 2020
NIH-funded project seeks to identify children at risk for MIS-C
Research effort will develop tests to predict severe COVID-19-linked illness.
The National Institutes of Health has announced research funding to encourage the development of approaches that identify children at high risk for developing Multisystem Inflammatory Syndrome in Children (MIS-C), thought to be a severe complication of COVID-19. Up to $20 million will be awarded to successful research proposals over four years.
Most children exposed to or infected with SARS-CoV-2, the virus that causes COVID-19, develop only a mild form of the illness. However, others go on to develop MIS-C(link is external), a severe, sometimes fatal, inflammation of organs and tissues, including the heart, lungs, kidneys, brain, skin and eyes. The new effort seeks to encourage studies of genetic, immune, viral, environmental, and other factors that influence how severe a case of COVID-19 will be and the chances of developing to MIS-C.
“We urgently need methods to distinguish children at high risk for MIS-C from those unlikely to experience major ill effects from the virus, so that we can develop early interventions to improve their outcomes, ” said Diana W. Bianchi, M.D., director of NIH’s Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)…

Thursday, August 6, 2020
NIH clinical trial testing remdesivir plus interferon beta-1a for COVID-19 treatment begins
A randomized, controlled clinical trial evaluating the safety and efficacy of a treatment regimen consisting of the antiviral remdesivir plus the immunomodulator interferon beta-1a in patients with coronavirus disease 2019 (COVID-19) has begun. The study, called the Adaptive COVID-19 Treatment Trial 3 (ACTT 3), is anticipated to enroll more than 1,000 hospitalized adults with COVID-19 at as many as 100 sites in the United States and abroad. The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, is sponsoring the trial…

Wednesday, August 5, 2020
NIH harnesses AI for COVID-19 diagnosis, treatment, and monitoring
Collaborative network to enlist medical imaging and clinical data sciences to reveal unique features of COVID-19.
The National Institutes of Health has launched the Medical Imaging and Data Resource Center (MIDRC), an ambitious effort that will harness the power of artificial intelligence and medical imaging to fight COVID-19. The multi-institutional collaboration, led by the National Institute of Biomedical Imaging and Bioengineering (NIBIB), part of NIH, will create new tools that physicians can use for early detection and personalized therapies for COVID-19 patients.
“This program is particularly exciting because it will give us new ways to rapidly turn scientific findings into practical imaging tools that benefit COVID-19 patients,” said Bruce J. Tromberg, Ph.D., NIBIB Director.  “It unites leaders in medical imaging and artificial intelligence from academia, professional societies, industry, and government to take on this important challenge.”
The features of infected lungs and hearts seen on medical images can help assess disease severity, predict response to treatment, and improve patient outcomes. However, a major challenge is to rapidly and accurately identify these signatures and evaluate this information in combination with many other  clinical symptoms and tests. The MIDRC goals are to lead the development and implementation of new diagnostics, including machine learning algorithms, that will allow rapid and accurate assessment of disease status and help physicians optimize patient treatment.
“This effort will gather a large repository of COVID-19 chest images,” explained Guoying Liu, Ph.D., the NIBIB scientific program lead on this effort, “allowing researchers to evaluate both lung and cardiac tissue data, ask critical research questions, and develop predictive COVID-19 imaging signatures that can be delivered to healthcare providers.”…

NIH-Moderna investigational COVID-19 vaccine shows promise in mouse studies
August 5, 2020 — Vaccine currently being evaluated in Phase 3 clinical testing.

NIH clinical trial to test antibodies and other experimental therapeutics for mild and moderate COVID-19
August 4, 2020 — Initial trial to determine if monoclonal antibodies can shorten severity of COVID-19 in outpatients.

NIH launches clinical trial to test antibody treatment in hospitalized COVID-19 patients
August 4, 2020 — ​Study aims to determine safety and efficacy of experimental monoclonal antibodies.


PATH [to 8 Aug 2020]
No new digest content identified.


Sabin Vaccine Institute [to 8 Aug 2020]
Statements and Press Releases
No new digest content identified.


UNAIDS [to 8 Aug 2020]
Selected Press Releases/Reports/Statements
4 August 2020
Virtual training for antiretroviral therapy prescribers launched in Papua New Guinea


UNICEF [to 8 Aug 2020]
Selected Press releases/Announcements
Press release
UNICEF loses life-saving supplies in Kinshasa warehouse fire

Press release
Geneva Palais briefing note on situation for children affected by Beirut explosions and UNICEF response

Press release
80,000 children displaced due to Beirut explosions – UNICEF
UNICEF scales up response and assistance to children and families

UNICEF sad and shocked at Beirut explosions, concerned about the wellbeing of children, and supporting partners on the ground
Statement from Ms. Yukie Mokuo, UNICEF Representative in Lebanon

Press release
UNICEF condemns attack in Cameroon’s Far North that reportedly killed 10 children

Support breastfeeding for a healthier planet
Joint message for World Breastfeeding Week 2020 by UNICEF Executive Director Henrietta H. Fore and WHO Director-General Tedros Adhanom Ghebreyesus

Press release
Children in Central America and the Caribbean facing dual threat of stronger hurricane season and COVID-19
Displacement and service interruption caused by storms could leave children and families more vulnerable to virus, UNICEF warns


Unitaid [to 8 Aug 2020]
Featured News
No new digest content identified.


Vaccination Acceptance Research Network (VARN) [to 8 Aug 2020]
No new digest content identified.


Vaccine Confidence Project [to 8 Aug 2020]
Research and Reports
Cross-Country Comparison of Public Awareness, Rumors, and Behavioral Responses to the COVID-19 Epidemic: Infodemiology Study
4 Aug 2020


Vaccine Education Center – Children’s Hospital of Philadelphia [to 8 Aug 2020]
No new digest content identified.


Wellcome Trust [to 8 Aug 2020]
No new digest content identified.


The Wistar Institute [to 8 Aug 2020]
Press Releases
No new digest content identified.


WFPHA: World Federation of Public Health Associations [to 8 Aug 2020]
Latest News
No new digest content identified.


World Organisation for Animal Health (OIE) [to 8 Aug 2020]
No new digest content identified.





ARM [Alliance for Regenerative Medicine] [to 8 Aug 2020]
Press Releases
New Report: Regenerative Medicine & Advanced Therapies Sector Thriving Despite COVID-19
August 6, 2020
Washington, DC
The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies, today announces the publication of its H1 2020 Global Sector Report, “Innovation in the Time of COVID-19.” The report provides an in-depth look at trends and metrics in the gene, cell, and tissue-based therapeutic sector in the midst of the pandemic.


BIO [to 8 Aug 2020]
Press Releases
Ensuring Scientific Justice by Building Bridges to Minority Communities is Centerpiece of BIOEquality Agenda
August 6, 2020
New focus on justice through equity in diverse clinical trials, STEM education and expanding entrepreneurship to undeserved communities will drive nation’s largest life science advocacy organization The Biotechnology Innovation Organization (BIO)…


DCVMN – Developing Country Vaccine Manufacturers Network [to 8 Aug 2020]
News; Upcoming events
Gavi/UNICEF SD information session on COVAX Facility
August 12th, 2020 13:00 – 15:30 CET


ICBA – International Council of Biotechnology Associations [to 8 Aug 2020]
No new digest content identified.


IFPMA [to 8 Aug 2020]
Selected Press Releases, Statements, Publications
No new digest content identified.


PhRMA [to 8 Aug 2020]
Selected Press Releases, Statements
Press Release
PhRMA Statement on the “Buy American” Executive Order
WASHINGTON, D.C. (August 6, 2020) – Pharmaceutical Research and Manufacturers of America President and CEO Stephen J. Ubl made the following statement:

“At a time when our nation’s priority should be to beat COVID-19, President Trump today signed yet another executive order that creates even more barriers to ongoing biopharmaceutical manufacturing and innovation. Companies are working around the clock to research and develop treatments and a vaccine for COVID-19. At the same time, they are working to ensure they have the capacity to manufacture the treatments and vaccines once approved so that every patient that needs them has access to them. These efforts are all hands on deck for the biopharmaceutical industry but each executive order issued by the administration adds another roadblock, making it harder to fight this pandemic.

“The administration is forcing biopharmaceutical companies to shift their critical attention and resources away from COVID-19 work to focus on making substantial changes to their business models necessary to comply with this and other recent executive orders. Increasing U.S. manufacturing of medicines is a laudable goal, but it cannot happen overnight and should not come at the expense of medical innovation or Americans’ access to the medicines they need.

“The recent executive orders also contradict and undermine each other, creating chaos in an industry that is on the frontlines of fighting COVID-19. With today’s ‘Buy American’ executive order, the administration effectively is taking the unprecedented step of mandating manufacturing of medicines in the United States. Yet at the same time, through the ‘most favored nation’ executive order, the administration is creating a huge disincentive to invest in U.S. biopharmaceutical research and manufacturing. Together, the result is less investment in U.S. innovation and the potential for major long-term supply chain disruptions – the opposite of wht America needs right now. None of these executive orders will help patients access or afford their medicines.

“The ‘Buy American’ executive order could disrupt the global pharmaceutical supply chain, jeopardizing our ability to respond to the current crisis and potentially leading to major long-term supply chain disruptions, including shortages. Rather than government mandates, we should look for policies that enable more domestic manufacturing without putting the stability of pharmaceutical supply chains at risk.”


Industry Watch [to 8 Aug 2020]
:: GSK launches national public awareness campaign to reverse steep decline in already low immunization rates for adults
PHILADELPHIA, Aug. 5, 2020 /PRNewswire/ — GSK today launched a national campaign to help increase low rates of vaccination among older adults. The campaign, Brought to You By Vaccines, will educate adults ages 50 and older about the value of vaccines and the urgent need to talk to their healthcare provider or pharmacist about the recommended vaccines they need or may have recently missed…